FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024
- None.
- None.
The acceptance by the FDA of Xspray Pharma's resubmission of the New Drug Application for Dasynoc® represents a pivotal step forward in the treatment of chronic myeloid leukemia (CML). Dasynoc®, an amorphous form of dasatinib, is purported to have improved properties over the crystalline form currently available. From a medical standpoint, the potential benefits of Dasynoc® lie in its optimized pharmacokinetic profile, which could lead to better patient outcomes in terms of efficacy and side effect management.
Should the FDA grant approval by the PDUFA date, the availability of Dasynoc® could mean an expanded arsenal of therapeutic options for oncologists and their patients. It is important to monitor how this new formulation compares with existing CML treatments in terms of response rates, progression-free survival and overall survival, as well as its side effect profile. This will ultimately determine its place in therapy and impact on patient care.
The assignment of a PDUFA date to Xspray Pharma's Dasynoc® is a significant event that can influence the company's market performance. Investors closely watch such milestones as they often lead to stock price volatility. The market impact hinges on the potential of Dasynoc® to capture market share in the CML treatment space, which is currently dominated by a few key players.
The successful commercialization of Dasynoc®, should it receive FDA approval, will depend on effective marketing strategies, competitive pricing and insurance coverage. Xspray Pharma's strategic planning for a commercial launch indicates confidence in their product's market potential. However, the actual market uptake of Dasynoc® will be a critical factor to watch post-launch, as it will affect the company's revenue and growth trajectory.
The FDA's acceptance of the NDA resubmission for Dasynoc® and the setting of a PDUFA date are material events that could have a significant impact on Xspray Pharma's financial future. The market often reacts positively to such regulatory advancements, potentially leading to an increase in investor confidence and stock value.
From a financial perspective, the cost implications of the ongoing preparation for commercial launch and the outcomes of the patent litigation settlement with Bristol Myers Squibb are also of interest. The company's ability to manage these expenses while investing in the commercialization process will be key to its financial health. Additionally, the potential revenue from Dasynoc®, if approved, would need to be evaluated against the development and marketing costs to assess the long-term financial benefits for Xspray Pharma and its stakeholders.
With an established PDUFA date set to 31st of July, Xspray Pharma continues to strategically plan for the commercial launch of Dasynoc® on September 1, 2024. These dates align with the company’s comprehensive preparation following the patent litigation settlement with Bristol Myers Squibb (BMS), paving the way for Dasynoc® to become a new option for chronic myeloid leukemia (CML) treatment pending FDA approval.
“With the new time line communicated by the FDA, I am pleased to confirm that Xspray Pharma is on track to launch our lead product candidate Dasynoc® on September 1 if approved, as previously communicated. We appreciate the FDA’s diligent review of our resubmission and look forward to collaborating closely with the agency in the lead-up to the PDUFA date,” said Per Andersson, CEO of Xspray Pharma AB. “Our team is fully committed to addressing the FDA’s requirements and ensuring that healthcare providers and patients have clear, comprehensive information on Dasynoc®’s dosing and administration.”
Dasynoc®, an optimized version of dasatinib, highlights Xspray Pharma’s dedication to advancing cancer treatment through innovative drug formulations. The product candidate has the potential to become a best-in-class product with a strong patent position for amorphous dasatinib products with improved properties for patients with CML. As the PDUFA date approaches, the company remains focused on its goal to improve the lives of those affected by CML with this novel therapy.
About Xspray Pharma AB
Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit www.xspraypharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the regulatory approval process and potential commercial launch of Dasynoc®. Actual results may vary based on the FDA’s final decision and other factors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212511634/en/
Xspray US-Media
Charlotte Wray
RXMD
cwray@rxmedyn.com
646-599-8601
For additional information
Per Andersson, PhD, CEO
Xspray Pharma AB
Mob: +46 (0) 706 88 23 48
E-mail: per.andersson@xspray.com
Source: Xspray Pharma
FAQ
When is the PDUFA date set for Xspray Pharma's Dasynoc®?
What is Dasynoc® and what is its potential in cancer treatment?
When does Xspray Pharma plan to launch Dasynoc®?
Who is the CEO of Xspray Pharma AB?
What milestone has Xspray Pharma recently achieved regarding FDA approval?
